Next Article in Journal
Anti-Mycobacterial Evaluation of 7-Chloro-4-Aminoquinolines and Hologram Quantitative Structure–Activity Relationship (HQSAR) Modeling of Amino–Imino Tautomers
Next Article in Special Issue
Synthesis and Antiproliferative Activity of Novel Heterocyclic Indole-Trimethoxyphenyl Conjugates
Previous Article in Journal / Special Issue
Chiral Derivatives of Xanthones: Investigation of the Effect of Enantioselectivity on Inhibition of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(2), 51;

Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds

Institute of Chemistry, São Paulo State University (UNESP), Araraquara 14800060, Brazil
School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800903, Brazil
The best presentation at the 2nd International Electronic Conference on Medicinal Chemistry.
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Received: 4 April 2017 / Revised: 9 May 2017 / Accepted: 29 May 2017 / Published: 1 June 2017
Full-Text   |   PDF [5164 KB, uploaded 1 June 2017]   |  


Tuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest number of deaths worldwide. The increased number of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years. The scenario of drug discovery becomes alarming when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compounds with potent antituberculosis activity against MDR-TB strains. Herein, active compounds against MDR-TB with minimum inhibitory concentrations (MICs) less than 11 µM and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed. View Full-Text
Keywords: tuberculosis; drug discovery; antitubercular compounds; multidrug-resistant tuberculosis tuberculosis; drug discovery; antitubercular compounds; multidrug-resistant tuberculosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Fernandes, G.F.S.; Man Chin, C.; Dos Santos, J.L. Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds . Pharmaceuticals 2017, 10, 51.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top